肝细胞癌局部区域治疗后[68Ga]Ga-FAPI-04 PET/CT评估存活肿瘤
本研究回顾性纳入37例肝细胞癌局部区域治疗患者的51个病灶,比较[68Ga]Ga-FAPI-04 PET/CT与[18F]FDG PET/CT检测存活肿瘤的效能。结果显示[68Ga]Ga-FAPI-04的灵敏度和准确率高于[18F]FDG,特异度相当,且与多期CT/MRI诊断准确率相当并具互补作用。
要点
- [68Ga]Ga-FAPI-04 PET/CT检测存活肿瘤的灵敏度96.0%高于[18F]FDG的36.0%,准确率94.1%高于68.6%。
- 两种显像剂特异度相当(92.3% vs. 100%),存活肿瘤中[68Ga]Ga-FAPI-04的SUVmax和TBR均高于[18F]FDG。
- [68Ga]Ga-FAPI-04 PET/CT与多期CT/MRI对存活肿瘤检测无显著差异,部分病例可互补。
核心结论
- [68Ga]Ga-FAPI-04 PET/CT诊断肝细胞癌局部区域治疗后存活肿瘤的灵敏度和准确率高于[18F]FDG PET/CT,与多期CT/MRI诊断准确率相当并具互补作用。
- 总体而言,[68Ga]Ga-FAPI-04 PET/CT可能在肝细胞癌局部区域治疗后的监测中发挥重要作用。
研究设计与样本
- 回顾性纳入来自前瞻性母研究(ChiCTR2000039099)的37例肝细胞癌局部区域治疗患者,共51个病灶,行[18F]FDG和[68Ga]Ga-FAPI-04序贯PET/CT。
- 以病理检查为存活肿瘤诊断金标准,临床随访为参考标准,计算并分析[68Ga]Ga-FAPI-04和[18F]FDG PET/CT及多期CT/MRI检测存活肿瘤的诊断准确率。
主要发现
- [68Ga]Ga-FAPI-04 PET/CT检测存活肿瘤的灵敏度为96.0%(24/25),[18F]FDG PET/CT为36.0%(9/25),p < 0.001。
- [68Ga]Ga-FAPI-04 PET/CT的准确率为94.1%(48/51),[18F]FDG PET/CT为68.6%(35/51),p = 0.004。
- 两者特异度相当:[68Ga]Ga-FAPI-04为92.3%(24/26),[18F]FDG为100%(26/26)。
- 存活肿瘤患者中[68Ga]Ga-FAPI-04 PET/CT的SUVmax为9.80、TBR为9.93,均高于[18F]FDG PET/CT的3.60和1.57(均p < 0.001)。
- [68Ga]Ga-FAPI-04 PET/CT上存活肿瘤的SUVmax和TNR均高于肿瘤坏死、良性边缘和正常肝(均p < 0.001),且呈结节状、肿块样或不规则放射性摄取。
关键数值与推荐
- [68Ga]Ga-FAPI-04 PET/CT与多期CT/MRI对存活肿瘤检测的差异无统计学意义(均p > 0.05),部分病例两者互补。
- 存活肿瘤诊断以病理检查为金标准,临床随访为参考标准。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the efficacy of [68Ga]Ga-FAPI-04 PET/CT for assessing viable tumours (VTs) after local regional treatment (LRT) in hepatocellular carcinoma (HCC) patients. The related imaging features of HCC after LRT are preliminarily discussed. METHODS: A cohort of 37 LRT patients with HCC (encompassing 51 lesions) was retrospectively included from a prospective parent study (ChiCTR2000039099), and sequential PET/CT using [18F]FDG and [68Ga]Ga-FAPI-04 was performed. The diagnostic accuracies of [68Ga]Ga-FAPI-04 and [18F]FDG PET/CT and multiphasic CT/MRI for detecting VTs after LRT were calculated and analysed. Pathological examination was considered the gold standard for VT diagnosis, and clinical follow-up was used as the reference standard. The SUVmax and tumour-to-background ratio (TBR) derived from [18F]FDG and [68Ga]Ga-FAPI-04 PET/CT were calculated and compared. Moreover, the SUVmax, target-to-normal liver ratio (TNR) of VT, tumour necrosis (TN), benign rim (BR), and normal liver (NL) from different imaging modalities after LRT for HCC were compared. RESULTS: Both the sensitivity (96.0% [24/25] vs. 36.0% [9/25], p < 0.001) and accuracy (94.1%, [48/51] vs. 68.6% [35/51], p = 0.004) of [68Ga]Ga-FAPI-04 PET/CT for detecting VTs after LRT were greater than those of [18F]FDG PET/CT, whereas their specificities were comparable (92.3% [24/26] vs. 100% [26/26]). Notably, [68Ga]Ga-FAPI-04 PET/CT had a greater SUVmax (9.80 vs. 3.60) and TBR (9.93 vs. 1.57) than [18F]FDG PET/CT in VT patients (all p < 0.001). Furthermore, VT had a greater SUVmax and TNR than did TN, BR, and NL on [68Ga]Ga-FAPI-04 PET/CT (all p < 0.001) and exhibited morphologic nodular, mass-like, or irregular tracer uptake. Although no significant differences were observed for VT detection (all p > 0.05), [68Ga]Ga-FAPI-04 PET/CT and multiphasic CT/MRI complemented each other in some cases. CONCLUSION: [68Ga]Ga-FAPI-04 PET/CT not only presented higher sensitivity and accuracy than [18F]FDG PET/CT for diagnosing VTs after LRT for HCC but also showed comparable diagnostic accuracy and complementary roles with multiphasic CT/MRI. Overall, [68Ga]Ga-FAPI-04 PET/CT may play an essential role in surveillance after LRT for HCC. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR2000039099. Registered 17 October 2020.
引用
- Zhu D, Song S, Zou S, et al. Assessment of viable tumours by [68Ga]Ga-FAPI-04 PET/CT after local regional treatment in patients with hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2025. PMID: 39831967. doi:10.1007/s00259-024-07062-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。